Profile data is unavailable for this security.
About the company
Polypeptide Group AG is a Switzerland-based Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.
- Revenue in CHF (TTM)309.47m
- Net income in CHF-49.00m
- Incorporated2021
- Employees1.20k
- LocationPolyPeptide Group AGNeuhofstrasse 24BAAR 6340SwitzerlandCHE
- Phone+41 435020580
- Websitehttps://www.polypeptide.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vetoquinol SA | 504.29m | 52.94m | 1.06bn | 2.48k | 20.02 | 2.11 | 13.82 | 2.11 | 4.70 | 4.70 | 44.73 | 44.53 | 0.7876 | 2.39 | 5.74 | 213,157.90 | 8.27 | 7.09 | 10.44 | 9.40 | 50.31 | 61.27 | 10.50 | 8.84 | 1.86 | -- | 0.0324 | 16.48 | -1.95 | 7.54 | 15.76 | 8.91 | 5.98 | 12.11 |
| ANI Pharmaceuticals Inc | 466.30m | 19.86m | 1.08bn | 642.00 | 49.78 | 2.74 | 14.62 | 2.31 | 1.19 | 1.19 | 27.93 | 22.81 | 0.6055 | 1.81 | 3.18 | 839,490.60 | 3.04 | -2.83 | 3.56 | -3.35 | 61.34 | 60.18 | 5.01 | -6.15 | 3.07 | 3.10 | 0.3725 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Ocular Therapeutix Inc | 52.86m | -119.71m | 1.08bn | 267.00 | -- | 3.29 | -- | 20.39 | -1.09 | -1.09 | 0.5249 | 2.43 | 0.191 | 2.36 | 2.12 | 228,827.70 | -43.26 | -46.70 | -47.93 | -54.18 | 90.84 | 89.36 | -226.46 | -228.65 | 16.55 | -11.30 | 0.1509 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| FAES Farma SA | 453.64m | 92.67m | 1.08bn | 746.00 | 11.56 | 1.64 | 9.73 | 2.39 | 0.3113 | 0.3113 | 1.52 | 2.20 | 0.5974 | 1.18 | 3.68 | 272,376.40 | 12.17 | 13.06 | 14.02 | 15.20 | 66.55 | 64.10 | 20.38 | 19.79 | 1.64 | -- | 0.0598 | -- | 2.83 | 6.83 | 2.63 | 12.24 | 39.26 | 52.23 |
| Polypeptide Group AG | 309.47m | -49.00m | 1.10bn | 1.20k | -- | 3.02 | -- | 3.56 | -1.48 | -1.48 | 9.34 | 11.02 | 0.5137 | 2.31 | 5.08 | 257,463.10 | -8.13 | 2.59 | -10.37 | 3.26 | 2.81 | 23.73 | -15.83 | 4.58 | 1.12 | -1.56 | 0.2466 | 15.79 | 14.60 | 12.36 | -762.29 | -- | 25.40 | -- |
| Zhejiang Hisun Pharmaceutical Co., Ltd. | 1.22bn | -9.32m | 1.12bn | 8.06k | -- | 1.12 | -- | 0.9231 | -0.0823 | -0.0823 | 8.45 | 6.86 | 0.5535 | 3.32 | 4.53 | 1,244,871.00 | -0.5084 | 1.95 | -0.8569 | 3.77 | 38.35 | 40.58 | -0.9187 | 3.43 | 0.6303 | -- | 0.4158 | 26.07 | -13.82 | 0.3618 | -119.05 | -- | -31.58 | -- |
| Aurisco Pharmaceutical Co Ltd | 157.08m | 39.48m | 1.13bn | 1.52k | 28.58 | 4.48 | -- | 7.19 | 0.803 | 0.803 | 3.18 | 5.12 | 0.5404 | 1.17 | 4.99 | 852,082.90 | 13.57 | 12.40 | 16.46 | 14.33 | 56.90 | 51.26 | 25.12 | 23.05 | 1.72 | -- | 0.116 | 25.15 | 25.24 | 17.02 | 37.23 | 16.16 | 26.54 | -- |
| Harrow Inc | 133.37m | -29.05m | 1.14bn | 315.00 | -- | 22.46 | -- | 8.53 | -0.9508 | -0.9508 | 4.38 | 1.65 | 0.581 | 4.95 | 4.39 | 489,352.40 | -12.66 | -10.86 | -14.77 | -12.71 | 71.16 | 70.75 | -21.78 | -15.35 | 2.43 | -0.3518 | 0.7608 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Neuren Pharmaceuticals Ltd | 135.62m | 89.65m | 1.14bn | -- | 12.76 | 9.67 | 12.69 | 8.39 | 1.22 | 1.22 | 1.84 | 1.61 | 1.63 | -- | 21.92 | -- | 107.87 | 49.80 | 127.30 | 55.37 | -- | -- | 66.10 | 50.10 | -- | -- | 0.00 | 0.00 | 1,403.22 | 76.78 | 85,270.11 | 119.64 | -- | -- |
| Industri Jamu dn Frms Sd Mncl Tbk PT | 210.19m | 61.31m | 1.21bn | 3.52k | 19.71 | 6.31 | 17.86 | 5.75 | 37.03 | 37.03 | 126.95 | 115.64 | 1.03 | 3.20 | 5.05 | 1,104,590,000.00 | 30.07 | 26.42 | 32.59 | 30.33 | 58.94 | 55.93 | 29.17 | 28.33 | 4.93 | 56.71 | 0.0014 | 95.17 | -7.75 | 5.23 | -13.95 | 7.45 | -27.13 | 11.37 |
Data as of Aug 15 2024. Currency figures normalised to PolyPeptide Group AG's reporting currency: Swiss Franc CHF
20.21%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Premier Fund Managers Ltd.as of 31 Dec 2023 | 1.71m | 5.17% |
| PRIMECAP Management Co.as of 31 Dec 2023 | 1.06m | 3.20% |
| Newtyn Management LLCas of 04 Jul 2024 | 993.57k | 3.00% |
| T. Rowe Price International Ltd.as of 04 Jan 2023 | 990.44k | 2.99% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 528.50k | 1.60% |
| BlackRock Investment Management (UK) Ltd.as of 30 Jun 2024 | 379.27k | 1.15% |
| HBM Partners AG (Investment Management)as of 31 Mar 2024 | 320.00k | 0.97% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 242.73k | 0.73% |
| Credit Suisse Asset Management (Schweiz) AGas of 31 Jul 2024 | 234.88k | 0.71% |
| UBS Asset Management Switzerland AGas of 02 Jul 2024 | 230.92k | 0.70% |
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
